Table 2.
Summary of included retrospective studies.
| Author | Year | Title | Study Design | Inclusion Criteria | EGFR Mutant (%) | Treatment Line | Treatment Arms | Time between ICI and TKI (Days) | Median Age (Range), Years | Sample Size (Female %) | Adverse Event Reported |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ito et al. | 2022 | Treatment with immune checkpoint inhibitors after EGFR-TKIs in EGFR-mutated lung cancer | Multiple institutions (Iwate Medical University Hospital, Iwate Prefectural Central Hospital, and Miyagi Cancer Center) retrospective study |
EGFR mutant NSCLC previously treated with TKI | Ex19del/ L858R (25%) T790M (8%) |
≥s | G/E/Af/O followed by N/P/At | 139 (1–707) | 67 (38–80) | 25 (40%) | ILD |
| Schoenfeld et al. | 2019 | Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib | Single institution (Memorial Sloan Kettering Cancer Center) retrospective study | EGFR mutant NSCLC treated with PD-(L)1 blockers and EGFR-TKI irrespective of drug sequence | NA | s | Arm 1: N/P/At/D followed by O Arm 2: sequential osimertinib followed by N/P/At/D |
Arm 1: 61 (12–1446) Arm 2: 5 (1–256) |
Arm 1: 61 (30–79) Arm 2: 56 (36–85) |
Arm 1: 41 (66%)Arm 2: 29 (83% | Severe immune related adverse events (4 G3 pneumonitis, 1 G3 colitis, 1 G4 hepatitis) |
| Uchida et al. | 2019 | Different incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancer | Single institution (Saitama medical university international medical center) retrospective study | Advanced EGFR mutant patients who receive TKI immediately before and/or after N or P | Ex19del/ L858R (100%) |
≥s | O or Af before or after N or P | NA | 69 (44–80) | 26 (62%) | ILD |
| Oshima et al. | 2018 | EGFR–TKI-associated interstitial pneumonitis in nivolumab-treated patients with non–small cell lung cancer |
Database study of US FDA Adverse Event Reporting System | EGFR mutant NSCLC | NA | NA | N/P/At in combination with Af/E/G/O | NA | Without N and TKI: 63 (NA) Without N, with TKI: 69 (NA). With N, without TKI: 66 (NA) With N and TKI: 64 (NA) |
20516 | ILD |
| Kotake et al. | 2017 | High incidence of interstitial lung disease following practical use of osimertinib in patients who had undergone immediate prior nivolumab therapy | Single institution (Shizuoka Cancer center) retrospective study | Advanced EGFR mutant NSCLC and disease progression on or after EGFR TKI | T790M (100%) | ≥s | N followed by O | In patients with ILD: 14 (7–28) In patients without ILD: 49 (28–119) |
Median age NA In patients with ILD: 4 < 70 In patients without ILD: 10 < 70, 5 > 70 |
19 | ILD |
Af, afatinib; At, atezolizumab; D, durvalumab; E, erlotinib; EGFR, epidermal growth factor receptor; G, gefitinib; G, grade; ICI, immune checkpoint inhibitor; ILD, interstial lung disease; NSCLC, non-small cell lung cancer; NA, not availabe; N, nivolumab; O, osimertinib; P, pembrolizumab; TKI, tyrosine kinase inhibitor.